Maze Therapeutics will present updated Phase 2 HORIZON data for MZE829, a dual-mechanism APOL1 inhibitor, in adults with APOL1-mediated kidney disease, alongside preclinical work on the SLC6A19 inhibitor MZE782. The company describes SLC6A19 inhibition as reducing nephrotoxin uptake and promoting a protective metabolic state in the proximal tubule, complementary to SGLT2 inhibition. Both programs target genetically and metabolically defined mechanisms of renal decline rather than downstream blood pressure or glycemic control.
Key Points
- Phase 2 HORIZON update for APOL1 inhibitor MZE829 to be presented
- SLC6A19 inhibition aims to reduce proximal tubule nephrotoxin uptake
- Preclinical data position MZE782 as complementary to SGLT2 inhibition
Longevity Analysis
Kidney function is a quiet determinant of healthspan: declining filtration capacity compounds cardiovascular risk, impairs clearance of metabolic waste, disturbs fluid and mineral balance, and alters hormonal signaling across the body. Targeting the proximal tubule's exposure to circulating toxins — removing the burden before attempting to repair the tissue — reflects the same logic that governs any durable intervention, with genotype determining who benefits. For clinicians, APOL1 status and early markers of tubular stress become actionable information rather than retrospective explanation.
Original published by LT Wire.